SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa

by Ysios Capital

3 months ago
SPVN06, retinitis pigmentosa, SparingVision

SparingVision today announces a key advancement in its Phase I/II clinical trial for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (...

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

by Ysios Capital

1 year ago
SPVN06, retinitis pigmentosa, PRODYGY

PRODYGY is a Phase I/II study to assess the safety, tolerability, efficacy and quality of life following a single subretinal injection of SPVN06 in the worst-seeing eye of adult patients with RP due t...

Innovative gene therapy for autosomal dominant retinitis pigmentosa

by DBGen Ocular Genomics

2 years ago
Retinitis pigmentosa, Gene Therapy, Retinal Dystrophy

Mutations in the RHO gene are the main cause of dominant forms of retinitis pigmentosa (RP). RHO dictates the production of rhodopsin, a transmembrane protein present in large quantities in the outer ...

Promising results for a first-in-class Usher syndrome IIA therapy

by DBGen Ocular Genomics

3 years ago
Retinitis pigmentosa, Usher syndrome, Therapy, biotechnology

The Dutch biotechnology company ProQR has just presented (March 2021) the first results of a clinical trial, named Stellar, with QR-421a, an antisense oligonucleotide designed to stop vision loss o...

SparingVision Raises €44.5 Million in a round led by 4BIO Capital and UPMC Enterprises, and included Jeito Capital and Ysios Capital

by Ysios Capital

4 years ago
retinitis pigmentosa, SparingVision, 4BIO Capital, UPMC Enterprises, Jeito Capital, Ysios Capital, Bpifrance, Foundation Fighting Blindness

SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...

Un nuevo modelo de ratón ayuda a comprender las distrofias hereditarias de retina causadas por el gen ‘CERKL’

by CIBERER - Centro de Investigación Biomédica en Red de Enfermedades Raras

4 years ago
retinitis pigmentosa, distrofias hereditarias, retina, gen CERKL

Mutaciones en el gen CERKL son una causa prevalente de dos distrofias hereditarias de retina, la retinitis pigmentosa y la distrofia de conos y bastones, pero el papel funcional de este gen en la reti...

Advances in gene therapy for retinitis pigmentosa due to RPGR gene mutation

by DBGen Ocular Genomics

4 years ago
Retinal Dystrophy, Retinitis pigmentosa, Gene Therapy

In the first months of 2020, positive results in gene therapy of X-linked retinitis pigmentosa (XLRP) have been reported. XLRP is an inherited genetic disorder that causes progressive vision loss, mai...

Expertos de EE UU consiguen recuperar parcialmente la visión en roedores

by Agencia Sinc

4 years ago
visión, retina, ceguera, retinitis pigmentosa, degeneración macular, retinopatía diabética

Un estudio, publicado en la revista Nature, muestra la restauración parcial de la visión en ratones ciegos mediante un método que genera químicamente nuevos fotorreceptores, encargados de captar l...

Antioxidants, key to combating retinal degeneration

by BMF Barcelona Macula Foundation: Research for Vision

5 years ago
nutrition, macular degeneration, AMD, eye diseases, prevention, Retinitis Pigmentosa, Antioxidants, photoreceptors

Good nutrition is essential in the prevention of many pathologies and this applies to eyes too. In the case of ocular diseases such as age-related macular degeneration (AMD), cataracts, glaucoma and c...

The Barcelona Macula Foundation, committed to progress on Retinitis Pigmentosa

by BMF Barcelona Macula Foundation: Research for Vision

5 years ago
BMF, Retinitis Pigmentosa, retina, blindness

Once again this year the Barcelona Macula Foundation is adding its voice to World Retinitis Pigmentosa Day. As part of its commitment, the BMF is collaborating in the clinical trial the company Reneur...

The Barcelona Macula Foundation participates in World Rare Disease Day and continues researching into Stargardt’s disease and Retinitis Pigmentosa

by BMF Barcelona Macula Foundation: Research for Vision

5 years ago
BMF, Rare diseases, Stargardt's disease, Retinitis Pigmentosa

For another year, the Barcelona Macula Foundation (BMF) is participating in World Rare Disease Day, whose main aim is to sensitise, educate and inform the public about these pathologies and positio...

Patients with retinitis pigmentosa in pole position

by Universidad del País Vasco

5 years ago
retinitis pigmentosa

Thanks to the clinical and genetic study made of all the patients with retinitis pigmentosa in Gipuzkoa by the UPV/EHU’s Department of Ophthalmology, Hospital Donostia, Biodonostia and Begisare, the...